BACKGROUND: Crohn's disease (CD) is considered a contraindication to ileal pouch--anal anastomosis (IPAA). In this study, we compare outcomes of CD and ulcerative colitis (UC) patients undergoing IPAA. METHODS: Patients were considered to have CD before surgery based on a history of small bowel disease, perianal disease, noncrypt-associated granuloma, or pretreatment skip colonic lesions. Patients were prospectively assessed for pouchitis or CD. Postoperative CD (pouch inflammation into the afferent limb or pouch fistula) or pouch failure (need for permanent diversion) were assessed. Preoperative serum was assayed for IBD-associated antibodies using enzyme-linked immunosorbent assay (ELISA). RESULTS: Seventeen patients with preoperative CD were identified. Seven (41%) patients developed postoperative recurrent CD in the afferent limb (n = 3) or pouch fistulizing disease (n = 4). One patient (6%) required pouch excision. The incidence of postoperative CD was higher (P = 0.002) in preoperative CD patients (41%) than UC patients (11%). There was no significant difference in pouchitis or pouch failure. There was also no significant difference in any preoperative clinical feature between patients with or without postoperative CD. Afferent limb inflammation developed in three (50%) of the six patients with pANCA+/OmpC- expression compared to none of the 11 patients without this serologic profile (P = 0.03). CONCLUSIONS: Although the intentional use of IPAA in CD has a higher incidence of postoperative disease vs. UC patients, there was no significant difference in pouch failure. Demographics, clinical features, and serologic factors do not predict outcome of CD patients undergoing IPAA. IBD serology may identify the phenotype manifestation of postoperative recurrent CD.
BACKGROUND:Crohn's disease (CD) is considered a contraindication to ileal pouch--anal anastomosis (IPAA). In this study, we compare outcomes of CD and ulcerative colitis (UC) patients undergoing IPAA. METHODS:Patients were considered to have CD before surgery based on a history of small bowel disease, perianal disease, noncrypt-associated granuloma, or pretreatment skip colonic lesions. Patients were prospectively assessed for pouchitis or CD. Postoperative CD (pouch inflammation into the afferent limb or pouch fistula) or pouch failure (need for permanent diversion) were assessed. Preoperative serum was assayed for IBD-associated antibodies using enzyme-linked immunosorbent assay (ELISA). RESULTS: Seventeen patients with preoperative CD were identified. Seven (41%) patients developed postoperative recurrent CD in the afferent limb (n = 3) or pouch fistulizing disease (n = 4). One patient (6%) required pouch excision. The incidence of postoperative CD was higher (P = 0.002) in preoperative CDpatients (41%) than UC patients (11%). There was no significant difference in pouchitis or pouch failure. There was also no significant difference in any preoperative clinical feature between patients with or without postoperative CD. Afferent limb inflammation developed in three (50%) of the six patients with pANCA+/OmpC- expression compared to none of the 11 patients without this serologic profile (P = 0.03). CONCLUSIONS: Although the intentional use of IPAA in CD has a higher incidence of postoperative disease vs. UC patients, there was no significant difference in pouch failure. Demographics, clinical features, and serologic factors do not predict outcome of CDpatients undergoing IPAA. IBD serology may identify the phenotype manifestation of postoperative recurrent CD.
Authors: Carl J Brown; Anthony R Maclean; Zane Cohen; Helen M Macrae; Brenda I O'Connor; Robin S McLeod Journal: Dis Colon Rectum Date: 2005-08 Impact factor: 4.585
Authors: George E Reese; Richard E Lovegrove; Henry S Tilney; Takayuki Yamamoto; Alexander G Heriot; Victor W Fazio; Paris P Tekkis Journal: Dis Colon Rectum Date: 2007-02 Impact factor: 4.585
Authors: E A Vasiliauskas; S E Plevy; C J Landers; S W Binder; D M Ferguson; H Yang; J I Rotter; A Vidrich; S R Targan Journal: Gastroenterology Date: 1996-06 Impact factor: 22.682
Authors: Bo Shen; Victor W Fazio; Feza H Remzi; Conor P Delaney; Ana E Bennett; Jean-Paul Achkar; Aaron Brzezinski; Farah Khandwala; Wendy Liu; Marlene L Bambrick; Jane Bast; Bret Lashner Journal: Am J Gastroenterol Date: 2005-01 Impact factor: 10.864
Authors: Stephan R Targan; Carol J Landers; Huiying Yang; Michael J Lodes; Yingzi Cong; Konstantinos A Papadakis; Eric Vasiliauskas; Charles O Elson; Robert M Hershberg Journal: Gastroenterology Date: 2005-06 Impact factor: 22.682
Authors: Genevieve B Melton; Victor W Fazio; Ravi P Kiran; Jin He; Ian C Lavery; Bo Shen; Jean-Paul Achkar; James M Church; Feza H Remzi Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Gil Y Melmed; Phillip R Fleshner; Ovunc Bardakcioglu; Andrew Ippoliti; Eric A Vasiliauskas; Konstantinos A Papadakis; Marla Dubinsky; Carol Landers; Jerome I Rotter; Stephan R Targan Journal: Dis Colon Rectum Date: 2007-12-18 Impact factor: 4.585
Authors: Samuel D James; Paul E Wise; Tania Zuluaga-Toro; David A Schwartz; M Kay Washington; Chanjuan Shi Journal: World J Gastroenterol Date: 2014-09-28 Impact factor: 5.742
Authors: G Pellino; D S Keller; G M Sampietro; I Angriman; M Carvello; V Celentano; F Colombo; F Di Candido; S Laureti; G Luglio; G Poggioli; M Rottoli; S Scaringi; G Sciaudone; G Sica; L Sofo; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi Journal: Tech Coloproctol Date: 2020-03-14 Impact factor: 3.781
Authors: Sasha Taleban; Martijn G H Van Oijen; Eric A Vasiliauskas; Phillip R Fleshner; Bo Shen; Andrew F Ippoliti; Stephan R Targan; Gil Y Melmed Journal: Dig Dis Sci Date: 2015-10-05 Impact factor: 3.199
Authors: James Wt Toh; Peter Stewart; Matthew Jfx Rickard; Rupert Leong; Nelson Wang; Christopher J Young Journal: World J Gastroenterol Date: 2016-10-28 Impact factor: 5.742